PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34754326-10 2021 However, Nrf2 knockdown abolished these protective effects of DMF. Dimethyl Fumarate 62-65 NFE2 like bZIP transcription factor 2 Homo sapiens 9-13 34754326-0 2021 Dimethyl Fumarate Ameliorates Nucleus Pulposus Cell Dysfunction through Activating the Nrf2/HO-1 Pathway in Intervertebral Disc Degeneration. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 87-91 34754326-2 2021 Dimethyl fumarate (DMF) has been found to effectively depress oxidative stress and inflammation via the Nrf2 pathway. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 104-108 34754326-2 2021 Dimethyl fumarate (DMF) has been found to effectively depress oxidative stress and inflammation via the Nrf2 pathway. Dimethyl Fumarate 19-22 NFE2 like bZIP transcription factor 2 Homo sapiens 104-108 34754326-11 2021 Conclusion: Our data suggested that treatment with DMF mitigated LPS-induced oxidative stress, inflammation, and ER stress-associated apoptosis in NPCs via the Nrf2/HO-1 signaling pathway, thus reliving LPS-induced dysfunction of NPCs, which offered a novel potential pharmacological treatment strategy for IVDD. Dimethyl Fumarate 51-54 NFE2 like bZIP transcription factor 2 Homo sapiens 160-164 34292106-0 2022 A comparison study between dimethyl itaconate and dimethyl fumarate in electrophilicity, Nrf2 activation, and anti-inflammation in vitro. Dimethyl Fumarate 50-67 NFE2 like bZIP transcription factor 2 Homo sapiens 89-93 34426902-3 2021 Dimethyl fumarate (DMF) is an anti-inflammatory drug that exerts its effects through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 107-150 34426902-3 2021 Dimethyl fumarate (DMF) is an anti-inflammatory drug that exerts its effects through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 152-156 34426902-3 2021 Dimethyl fumarate (DMF) is an anti-inflammatory drug that exerts its effects through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. Dimethyl Fumarate 19-22 NFE2 like bZIP transcription factor 2 Homo sapiens 107-150 34426902-3 2021 Dimethyl fumarate (DMF) is an anti-inflammatory drug that exerts its effects through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. Dimethyl Fumarate 19-22 NFE2 like bZIP transcription factor 2 Homo sapiens 152-156 34426902-10 2021 Moreover, the expression of HO-1 and NQO-1 was upregulated in hASCs pretreated with DMF which confirms the activation of the Nrf2 pathway. Dimethyl Fumarate 84-87 NFE2 like bZIP transcription factor 2 Homo sapiens 125-129 34292106-1 2022 Dimethyl itaconate (DMI) is an analog of dimethyl fumarate (DMF), an approved NF-E2-related Factor 2 (Nrf2) activator for multiple sclerosis. Dimethyl Fumarate 41-58 NFE2 like bZIP transcription factor 2 Homo sapiens 78-100 34292106-1 2022 Dimethyl itaconate (DMI) is an analog of dimethyl fumarate (DMF), an approved NF-E2-related Factor 2 (Nrf2) activator for multiple sclerosis. Dimethyl Fumarate 41-58 NFE2 like bZIP transcription factor 2 Homo sapiens 102-106 34292106-1 2022 Dimethyl itaconate (DMI) is an analog of dimethyl fumarate (DMF), an approved NF-E2-related Factor 2 (Nrf2) activator for multiple sclerosis. Dimethyl Fumarate 60-63 NFE2 like bZIP transcription factor 2 Homo sapiens 78-100 34292106-1 2022 Dimethyl itaconate (DMI) is an analog of dimethyl fumarate (DMF), an approved NF-E2-related Factor 2 (Nrf2) activator for multiple sclerosis. Dimethyl Fumarate 60-63 NFE2 like bZIP transcription factor 2 Homo sapiens 102-106 35123595-3 2022 Meanwhile, the protein levels of nuclear factor-erythroid 2-related factor 2 (Nrf2) and E3 ubiquitin ligase HACE1 in Jurkat cells treated with DMF for 24 hours were evaluated by Western blot. Dimethyl Fumarate 143-146 NFE2 like bZIP transcription factor 2 Homo sapiens 33-76 35247778-5 2022 Dimethyl fumarate (DMF), targets the Nrf2 pathway, was approved by FDA for the clinical treatment of multiple sclerosis (MS), which is another autoimmune disease. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 37-41 35247778-5 2022 Dimethyl fumarate (DMF), targets the Nrf2 pathway, was approved by FDA for the clinical treatment of multiple sclerosis (MS), which is another autoimmune disease. Dimethyl Fumarate 19-22 NFE2 like bZIP transcription factor 2 Homo sapiens 37-41 35306364-3 2022 Although it has been revealed that DMF and MEF differentially modify specific Keap1 cysteine residues and result in the differential activation of Nrf2, how the modification of DMF and MEF impacts the biochemical properties of Keap1 has not been well characterized. Dimethyl Fumarate 35-38 NFE2 like bZIP transcription factor 2 Homo sapiens 147-151 35306364-3 2022 Although it has been revealed that DMF and MEF differentially modify specific Keap1 cysteine residues and result in the differential activation of Nrf2, how the modification of DMF and MEF impacts the biochemical properties of Keap1 has not been well characterized. Dimethyl Fumarate 177-180 NFE2 like bZIP transcription factor 2 Homo sapiens 147-151 35624879-1 2022 BACKGROUND: Dimethyl fumarate (DMF), a drug used for the treatment of multiple sclerosis (MS) and psoriasis, has been shown to activate the Keap1/Nrf2 antioxidant response. Dimethyl Fumarate 12-29 NFE2 like bZIP transcription factor 2 Homo sapiens 146-150 35624879-1 2022 BACKGROUND: Dimethyl fumarate (DMF), a drug used for the treatment of multiple sclerosis (MS) and psoriasis, has been shown to activate the Keap1/Nrf2 antioxidant response. Dimethyl Fumarate 31-34 NFE2 like bZIP transcription factor 2 Homo sapiens 146-150 35123595-3 2022 Meanwhile, the protein levels of nuclear factor-erythroid 2-related factor 2 (Nrf2) and E3 ubiquitin ligase HACE1 in Jurkat cells treated with DMF for 24 hours were evaluated by Western blot. Dimethyl Fumarate 143-146 NFE2 like bZIP transcription factor 2 Homo sapiens 78-82 33931960-0 2021 Dimethyl fumarate prevents ferroptosis to attenuate acute kidney injury by acting on NRF2. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 85-89 35141161-0 2022 Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 106-110 35141161-4 2022 DMF/Vem treatment induced cell death through inhibiting the expression and transcriptional activity of NRF2 thereby resulting in more reactive oxygen species (ROS) and via inhibiting the expression of YAP, a key downstream effector of Hippo pathway. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 103-107 33784961-7 2022 The other first-line drug, dimethyl fumarate, may afford protection against SARS-CoV-2 by activating the Nrf-2 pathway and reinforcing the cellular defences against oxidative stress. Dimethyl Fumarate 27-44 NFE2 like bZIP transcription factor 2 Homo sapiens 105-110 32672401-5 2021 Recent studies showed that DMF modifies the reactive cysteines in the BTB domain of Keap1 and thus activates Nrf2 transcription function. Dimethyl Fumarate 27-30 NFE2 like bZIP transcription factor 2 Homo sapiens 109-113 32672401-7 2021 The crystal structure of the complex, refined to 1.54 A resolution, revealed unexpected features: DMF binds (i) to the Nrf2 binding site (bottom region of Keap1-DC, site 1) with moderate interaction, and (ii) to the top region of Keap1-DC, near to the blade II (site 2). Dimethyl Fumarate 98-101 NFE2 like bZIP transcription factor 2 Homo sapiens 119-123 32672401-12 2021 Furthermore, the competitive binding assay in the presence of the Nrf2 peptide affirmed the direct binding of DMF at the Nrf2 binding region of Keap1-DC. Dimethyl Fumarate 110-113 NFE2 like bZIP transcription factor 2 Homo sapiens 66-70 32672401-12 2021 Furthermore, the competitive binding assay in the presence of the Nrf2 peptide affirmed the direct binding of DMF at the Nrf2 binding region of Keap1-DC. Dimethyl Fumarate 110-113 NFE2 like bZIP transcription factor 2 Homo sapiens 121-125 33396673-0 2020 Dimethyl Fumarate Promotes the Survival of Retinal Ganglion Cells after Optic Nerve Injury, Possibly through the Nrf2/HO-1 Pathway. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 113-117 33396641-2 2020 Several reports have demonstrated beneficial effects of NRF2 manipulation in animal models of disease, and one NRF2-activating drug, dimethyl fumarate, is already approved for the treatment of multiple sclerosis. Dimethyl Fumarate 133-150 NFE2 like bZIP transcription factor 2 Homo sapiens 111-115 33468560-6 2021 The nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-mediated oxidative stress response pathway was exclusively regulated by DMF, whereas apoptosis pathways were activated by MEF. Dimethyl Fumarate 127-130 NFE2 like bZIP transcription factor 2 Homo sapiens 4-47 33468560-6 2021 The nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-mediated oxidative stress response pathway was exclusively regulated by DMF, whereas apoptosis pathways were activated by MEF. Dimethyl Fumarate 127-130 NFE2 like bZIP transcription factor 2 Homo sapiens 49-53 33396673-1 2020 This study aimed to verify whether dimethyl fumarate (DMF) promotes the survival of retinal ganglion cells (RGCs) after optic nerve crush (ONC) accompanied by activation of the NF-E2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway. Dimethyl Fumarate 35-52 NFE2 like bZIP transcription factor 2 Homo sapiens 177-199 33396673-1 2020 This study aimed to verify whether dimethyl fumarate (DMF) promotes the survival of retinal ganglion cells (RGCs) after optic nerve crush (ONC) accompanied by activation of the NF-E2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway. Dimethyl Fumarate 35-52 NFE2 like bZIP transcription factor 2 Homo sapiens 201-205 33396673-1 2020 This study aimed to verify whether dimethyl fumarate (DMF) promotes the survival of retinal ganglion cells (RGCs) after optic nerve crush (ONC) accompanied by activation of the NF-E2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway. Dimethyl Fumarate 54-57 NFE2 like bZIP transcription factor 2 Homo sapiens 177-199 33396673-1 2020 This study aimed to verify whether dimethyl fumarate (DMF) promotes the survival of retinal ganglion cells (RGCs) after optic nerve crush (ONC) accompanied by activation of the NF-E2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway. Dimethyl Fumarate 54-57 NFE2 like bZIP transcription factor 2 Homo sapiens 201-205 33396673-3 2020 Furthermore, immunohistochemical and immunoblotting analyses were performed to study the activation of the Nrf2/HO-1 pathway using retinas treated with daily administration of DMF. Dimethyl Fumarate 176-179 NFE2 like bZIP transcription factor 2 Homo sapiens 107-111 33396673-5 2020 Immunohistochemical analysis showed that DMF administration increased the immunoreactivity for Nrf2 and HO-1, a potent antioxidant enzyme, in RGCs immunolabeled with RNA-binding protein with multiple splicing (RBPMS). Dimethyl Fumarate 41-44 NFE2 like bZIP transcription factor 2 Homo sapiens 95-99 33199994-9 2020 DMF also increased the anti-inflammatory and antioxidative ability of NP cells by promoting the activity of the Nrf2/HO-1 and PI3K/Akt signaling pathways, thus delaying IVDD. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 112-116 32811823-3 2020 One of the top compounds predicted to be therapeutic for ALD by our approach was dimethyl fumarate (DMF), an nuclear factor erythroid 2-related factor 2 (NRF2) inducer. Dimethyl Fumarate 81-98 NFE2 like bZIP transcription factor 2 Homo sapiens 109-152 33003644-5 2020 We used dimethyl-fumarate (DMF) and pioglitazone (pio) as agents activating NRF2 and PPAR-gamma, respectively, and two synthetic hybrids acting differently on the NRF2/ARE pathway. Dimethyl Fumarate 27-30 NFE2 like bZIP transcription factor 2 Homo sapiens 76-80 33087130-9 2020 The transcriptional and functional effects of dimethyl fumarate (DMF), an FDA approved drug which induces the NRF2 pathway, on host and parasite induced HBMVEC activation was characterized. Dimethyl Fumarate 46-63 NFE2 like bZIP transcription factor 2 Homo sapiens 110-114 33087130-9 2020 The transcriptional and functional effects of dimethyl fumarate (DMF), an FDA approved drug which induces the NRF2 pathway, on host and parasite induced HBMVEC activation was characterized. Dimethyl Fumarate 65-68 NFE2 like bZIP transcription factor 2 Homo sapiens 110-114 33087717-0 2020 Author Correction: SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Dimethyl Fumarate 149-166 NFE2 like bZIP transcription factor 2 Homo sapiens 53-57 33009401-0 2020 SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Dimethyl Fumarate 130-147 NFE2 like bZIP transcription factor 2 Homo sapiens 34-38 33009401-3 2020 Further, we uncover that NRF2 agonists 4-octyl-itaconate (4-OI) and the clinically approved dimethyl fumarate (DMF) induce a cellular antiviral program that potently inhibits replication of SARS-CoV2 across cell lines. Dimethyl Fumarate 111-114 NFE2 like bZIP transcription factor 2 Homo sapiens 25-29 33009401-6 2020 In conclusion, NRF2 agonists 4-OI and DMF induce a distinct IFN-independent antiviral program that is broadly effective in limiting virus replication and in suppressing the pro-inflammatory responses of human pathogenic viruses, including SARS-CoV2. Dimethyl Fumarate 38-41 NFE2 like bZIP transcription factor 2 Homo sapiens 15-19 32553625-4 2020 Dimethyl fumarate (DMF) is a potent activator of Nrf2 and has been shown to inhibit osteoclastogenesis. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 49-53 32553625-4 2020 Dimethyl fumarate (DMF) is a potent activator of Nrf2 and has been shown to inhibit osteoclastogenesis. Dimethyl Fumarate 19-22 NFE2 like bZIP transcription factor 2 Homo sapiens 49-53 32553625-8 2020 We also found that DMF inhibited the extracellular release of high mobility group box 1, associated with an up-regulation of heme oxygenase-1, likely mediated through Nrf2 activation. Dimethyl Fumarate 19-22 NFE2 like bZIP transcription factor 2 Homo sapiens 167-171 32863237-4 2020 Here, we investigated mechanisms of inflammation and cell death pathways induced by a variety of Nrf2 activators including dimethyl fumarate (DMF) and the endogenous metabolite itaconate. Dimethyl Fumarate 123-140 NFE2 like bZIP transcription factor 2 Homo sapiens 97-101 32863237-4 2020 Here, we investigated mechanisms of inflammation and cell death pathways induced by a variety of Nrf2 activators including dimethyl fumarate (DMF) and the endogenous metabolite itaconate. Dimethyl Fumarate 142-145 NFE2 like bZIP transcription factor 2 Homo sapiens 97-101 32708926-0 2020 Antioxidant and Anti-inflammatory Effect of Nrf2 Inducer Dimethyl Fumarate in Neurodegenerative Diseases. Dimethyl Fumarate 57-74 NFE2 like bZIP transcription factor 2 Homo sapiens 44-48 32708926-6 2020 DMF is a methyl ester of fumaric acid and acts as modulator of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway as well as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) translocation. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 67-110 32708926-6 2020 DMF is a methyl ester of fumaric acid and acts as modulator of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway as well as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) translocation. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 112-116 32784785-5 2020 This review focuses on results from clinical trials with four agents known to target NRF2 signaling in preclinical studies (dimethyl fumarate, bardoxolone methyl, oltipraz, and sulforaphane), and evaluates the successes and limitations of biomarkers focused on expression of NRF2 target genes and others, inflammation and oxidative stress biomarkers, carcinogen metabolism and adduct biomarkers in unavoidably exposed populations, and targeted and untargeted metabolomics. Dimethyl Fumarate 124-141 NFE2 like bZIP transcription factor 2 Homo sapiens 85-89 32756501-5 2020 In addition to the hypothesis that DMF is linked to the activation of NRF2 and NF-kB transcription factors, the neuroprotective action of DMF may be mediated by the activation of the glutathione (GSH) antioxidant pathway and the regulation of brain iron homeostasis. Dimethyl Fumarate 35-38 NFE2 like bZIP transcription factor 2 Homo sapiens 70-74 32811823-3 2020 One of the top compounds predicted to be therapeutic for ALD by our approach was dimethyl fumarate (DMF), an nuclear factor erythroid 2-related factor 2 (NRF2) inducer. Dimethyl Fumarate 81-98 NFE2 like bZIP transcription factor 2 Homo sapiens 154-158 32811823-3 2020 One of the top compounds predicted to be therapeutic for ALD by our approach was dimethyl fumarate (DMF), an nuclear factor erythroid 2-related factor 2 (NRF2) inducer. Dimethyl Fumarate 100-103 NFE2 like bZIP transcription factor 2 Homo sapiens 109-152 32811823-3 2020 One of the top compounds predicted to be therapeutic for ALD by our approach was dimethyl fumarate (DMF), an nuclear factor erythroid 2-related factor 2 (NRF2) inducer. Dimethyl Fumarate 100-103 NFE2 like bZIP transcription factor 2 Homo sapiens 154-158 32247228-0 2020 Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS. Dimethyl Fumarate (DMF), known for its mechanism of action targeting Nrf2 and related redox homeostasis, is an approved immunotherapy for patients with Multiple Sclerosis (PwMS) in the relapsing form. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 221-225 32247228-0 2020 Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS. Dimethyl Fumarate (DMF), known for its mechanism of action targeting Nrf2 and related redox homeostasis, is an approved immunotherapy for patients with Multiple Sclerosis (PwMS) in the relapsing form. Dimethyl Fumarate 152-169 NFE2 like bZIP transcription factor 2 Homo sapiens 221-225 32247228-0 2020 Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS. Dimethyl Fumarate (DMF), known for its mechanism of action targeting Nrf2 and related redox homeostasis, is an approved immunotherapy for patients with Multiple Sclerosis (PwMS) in the relapsing form. Dimethyl Fumarate 171-174 NFE2 like bZIP transcription factor 2 Homo sapiens 221-225 30051766-10 2019 DMF therapy may potentially result in bone marrow oedema due to inhibition of common upstream signalling pathways, including the Nrf2 signalling pathway. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 129-133 31650471-1 2019 BACKGROUND: Dimethyl fumarate (DMF) exerts anti-inflammatory effects in multiple sclerosis by activating the Nrf2 antioxidant pathway, which is also stimulated by acetylcholine via alpha-7 nicotinic acetylcholine receptors. Dimethyl Fumarate 12-29 NFE2 like bZIP transcription factor 2 Homo sapiens 109-113 31650471-1 2019 BACKGROUND: Dimethyl fumarate (DMF) exerts anti-inflammatory effects in multiple sclerosis by activating the Nrf2 antioxidant pathway, which is also stimulated by acetylcholine via alpha-7 nicotinic acetylcholine receptors. Dimethyl Fumarate 31-34 NFE2 like bZIP transcription factor 2 Homo sapiens 109-113 31688588-5 2019 Likewise, we summarize existing antioxidative therapies for chronic pancreatitis and discuss a novel nuclear factor erythroid 2-related factor 2 activator, dimethyl fumarate, and its potential to reduce fibrogenesis by downregulating pancreatic stellate cell activation. Dimethyl Fumarate 156-173 NFE2 like bZIP transcription factor 2 Homo sapiens 101-144 31279969-2 2019 DMF causes short-term oxidative stress and activates the antioxidant response via the transcription factor Nrf2 but its immunosuppressive effect is not well understood. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 107-111 32581803-8 2020 The Nrf2 activator dimethyl-fumarate (DMF; 10 muM) was used as a positive control. Dimethyl Fumarate 19-36 NFE2 like bZIP transcription factor 2 Homo sapiens 4-8 32316115-7 2020 Herein, we present the most recently studied Nrf2/Keap1 activators in pancreas for application in ICT: Dh404, dimethyl fumarate (DMF), and epigallocatechin gallate (EGCG). Dimethyl Fumarate 110-127 NFE2 like bZIP transcription factor 2 Homo sapiens 45-49 32316115-7 2020 Herein, we present the most recently studied Nrf2/Keap1 activators in pancreas for application in ICT: Dh404, dimethyl fumarate (DMF), and epigallocatechin gallate (EGCG). Dimethyl Fumarate 129-132 NFE2 like bZIP transcription factor 2 Homo sapiens 45-49 31658977-7 2019 Nrf2 activation in SOD1 mutant astrocytes with dimethyl fumarate restores calcium homeostasis and ameliorates motor neuron death. Dimethyl Fumarate 47-64 NFE2 like bZIP transcription factor 2 Homo sapiens 0-4 31300673-2 2019 The redox master regulator Nrf2, essential for redox balance, is a target of DMF, but its precise therapeutic mechanisms of action remain elusive. Dimethyl Fumarate 77-80 NFE2 like bZIP transcription factor 2 Homo sapiens 27-31 30587509-2 2019 DMF is known to act by depleting intracellular glutathione and modifying thiols on Keap1 protein, resulting in the stabilization of the transcription factor Nrf2, which in turn induces the expression of antioxidant response element genes. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 157-161 30820593-3 2019 It is believed that the mode of action of DMF involves both nuclear factor erythroid-derived 2-related factor (Nrf2)-dependent and independent pathways, which lead to an anti-inflammatory immune response due to type II myeloid cell and Th2 cell differentiation and neuroprotection. Dimethyl Fumarate 42-45 NFE2 like bZIP transcription factor 2 Homo sapiens 60-109 30820593-3 2019 It is believed that the mode of action of DMF involves both nuclear factor erythroid-derived 2-related factor (Nrf2)-dependent and independent pathways, which lead to an anti-inflammatory immune response due to type II myeloid cell and Th2 cell differentiation and neuroprotection. Dimethyl Fumarate 42-45 NFE2 like bZIP transcription factor 2 Homo sapiens 111-115 30256716-2 2019 Although the understanding of the complex nature of NRF2 signaling continues to grow, there is only one therapeutic targeting NRF2 for clinical use, dimethyl fumarate, used for the treatment of multiple sclerosis. Dimethyl Fumarate 149-166 NFE2 like bZIP transcription factor 2 Homo sapiens 126-130 29529529-1 2018 Recent research has outlined that Dimethyl Fumarate (DMF) functions as a gene regulator via multiple pathways, critical among which is the NRF2 cytoprotective cascade. Dimethyl Fumarate 34-51 NFE2 like bZIP transcription factor 2 Homo sapiens 139-143 29447051-0 2018 Targeting crosstalk between Nuclear factor (erythroid-derived 2)-like 2 and Nuclear factor kappa beta pathway by Nrf2 activator dimethyl fumarate in epileptogenesis. Dimethyl Fumarate 128-145 NFE2 like bZIP transcription factor 2 Homo sapiens 28-71 29447051-0 2018 Targeting crosstalk between Nuclear factor (erythroid-derived 2)-like 2 and Nuclear factor kappa beta pathway by Nrf2 activator dimethyl fumarate in epileptogenesis. Dimethyl Fumarate 128-145 NFE2 like bZIP transcription factor 2 Homo sapiens 113-117 29928650-0 2018 The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis. Dimethyl Fumarate 44-61 NFE2 like bZIP transcription factor 2 Homo sapiens 4-8 29928650-3 2018 Here, we focus on the relation between nuclear factor (erythroid-derived 2)-like 2 (NRF2) pathway induction under DMF therapy and the composition of the blood immune cell compartment and clinical efficacy in relapsing-remitting multiple sclerosis (MS) patients. Dimethyl Fumarate 114-117 NFE2 like bZIP transcription factor 2 Homo sapiens 84-88 29928650-5 2018 Results: Gene expression analysis proved activation of NRF2 signaling under DMF therapy that was paralleled by a temporal expansion of FoxP3+ regulatory T cells, CD56bright natural killer cells, plasmacytoid dendritic cells, and a decrease in CD8+ T cells, B cells, and type 1 myeloid dendritic cells. Dimethyl Fumarate 76-79 NFE2 like bZIP transcription factor 2 Homo sapiens 55-59 29928650-6 2018 In a subgroup of 28 patients with completely available clinical data, individuals with higher levels of the NRF2 target gene NAD(P)H quinone dehydrogenase 1 (NQO1) 4-6 weeks after DMF therapy initiation were more likely to achieve no evidence of disease activity status 1 year later. Dimethyl Fumarate 180-183 NFE2 like bZIP transcription factor 2 Homo sapiens 108-112 29928650-8 2018 Interpretation: We demonstrate that positive effects of DMF on the clinical outcome are paralleled by induction of the antioxidant NRF2 transcriptional pathway and a shift toward regulatory immune cell subsets in the periphery. Dimethyl Fumarate 56-59 NFE2 like bZIP transcription factor 2 Homo sapiens 131-135 29928650-9 2018 Our data identify a role of the NRF2 pathway as potential biomarker for DMF treatment in MS. Dimethyl Fumarate 72-75 NFE2 like bZIP transcription factor 2 Homo sapiens 32-36 28986302-5 2018 Human luteinized GCs were isolated and cultured, and hydrogen peroxide (H2O2) or Dimethylfumarates (DMF), an activator of Nrf2, were added to GCs to analyze the relationship between Nrf2 and antioxidants by quantitative RT-PCR. Dimethyl Fumarate 81-98 NFE2 like bZIP transcription factor 2 Homo sapiens 122-126 28986302-5 2018 Human luteinized GCs were isolated and cultured, and hydrogen peroxide (H2O2) or Dimethylfumarates (DMF), an activator of Nrf2, were added to GCs to analyze the relationship between Nrf2 and antioxidants by quantitative RT-PCR. Dimethyl Fumarate 81-98 NFE2 like bZIP transcription factor 2 Homo sapiens 182-186 28986302-5 2018 Human luteinized GCs were isolated and cultured, and hydrogen peroxide (H2O2) or Dimethylfumarates (DMF), an activator of Nrf2, were added to GCs to analyze the relationship between Nrf2 and antioxidants by quantitative RT-PCR. Dimethyl Fumarate 100-103 NFE2 like bZIP transcription factor 2 Homo sapiens 122-126 28986302-6 2018 The mRNA levels of Nrf2, catalase, superoxide dismutase 1 (SOD1), and 8-Oxoguanine DNA glycosylase (OGG1) were elevated by H2O2, and DMF treatment showed similar but pronounced effects through activation of Nrf2. Dimethyl Fumarate 133-136 NFE2 like bZIP transcription factor 2 Homo sapiens 19-23 28986302-6 2018 The mRNA levels of Nrf2, catalase, superoxide dismutase 1 (SOD1), and 8-Oxoguanine DNA glycosylase (OGG1) were elevated by H2O2, and DMF treatment showed similar but pronounced effects through activation of Nrf2. Dimethyl Fumarate 133-136 NFE2 like bZIP transcription factor 2 Homo sapiens 207-211 30283812-12 2018 Conclusion: Short-term PBMC transcriptome changes reflecting activation of the Nrf2 and inhibition of NFkappaB pathways distinguish patients who subsequently show a medium-term treatment response with DMF. Dimethyl Fumarate 201-204 NFE2 like bZIP transcription factor 2 Homo sapiens 79-83 29603404-5 2018 DMF and to some extent also MMF modulate the activity of certain cellular signalling proteins such as the nuclear factor (erythroid-derived 2)-like 2 (Nrf2), nuclear factor kappa B (Nf-kappaB) and the cellular concentration of cyclic adenosine monophosphate. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 151-155 29121589-6 2018 DMF induces the NRF2 transcriptional through a mechanism that involves KEAP1 but also PI3K/AKT/GSK-3-dependent pathways. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 16-20 29529529-1 2018 Recent research has outlined that Dimethyl Fumarate (DMF) functions as a gene regulator via multiple pathways, critical among which is the NRF2 cytoprotective cascade. Dimethyl Fumarate 53-56 NFE2 like bZIP transcription factor 2 Homo sapiens 139-143 29529529-4 2018 It is our hypothesis that while the NRF2-KEAP1 inhibitory complex is reported the main pharmacological target for DMF"s NRF dependent functions, no study to date has explored the effects of DMF on DJ-1"s expression, and vice-versa, the possibility of a regulatory inadequacy in the upstream, oxidant-responsive DJ-1 activator of the NRF2 cascade. Dimethyl Fumarate 114-117 NFE2 like bZIP transcription factor 2 Homo sapiens 36-40 28990726-3 2018 Dimethyl fumarate (DMF) is an orally bioavailable methyl ester of fumaric acid and activator of Nrf2 with potential neuroprotective and immunomodulating activities. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 96-100 28990726-3 2018 Dimethyl fumarate (DMF) is an orally bioavailable methyl ester of fumaric acid and activator of Nrf2 with potential neuroprotective and immunomodulating activities. Dimethyl Fumarate 19-22 NFE2 like bZIP transcription factor 2 Homo sapiens 96-100 28990726-8 2018 Our results showed important multi-protective effects of DMF pre-treatment from Abeta stimulation both in in vitro and ex vivo models, highlighting an Nrf2/NF-kappaB-dependent mechanism, which could provide a valuable support to the therapies for neurodegenerative diseases today. Dimethyl Fumarate 57-60 NFE2 like bZIP transcription factor 2 Homo sapiens 151-155 28156185-4 2017 OBJECTIVE: To investigate the activation of Nrf2 pathway following ex vivo stimulation of human peripheral blood mononuclear cells (PBMCs) with DMF or MMF, and in DMF-treated patients from two Phase 3 relapsing MS studies DEFINE and CONFIRM. Dimethyl Fumarate 144-147 NFE2 like bZIP transcription factor 2 Homo sapiens 44-48 29507676-2 2018 We previously observed that the antitumoral effect of Dimethyl fumarate (DMF) is dependent of NRF2 pathway inhibition. Dimethyl Fumarate 54-71 NFE2 like bZIP transcription factor 2 Homo sapiens 94-98 29507676-2 2018 We previously observed that the antitumoral effect of Dimethyl fumarate (DMF) is dependent of NRF2 pathway inhibition. Dimethyl Fumarate 73-76 NFE2 like bZIP transcription factor 2 Homo sapiens 94-98 29507676-10 2018 Our results suggest for the first time that the dependence on NRF2 observed in mutated KRAS malignant cells makes them more sensitive to the cytotoxic effect of DMF, which thus opens up new prospects for the therapeutic applications of DMF. Dimethyl Fumarate 161-164 NFE2 like bZIP transcription factor 2 Homo sapiens 62-66 29507676-10 2018 Our results suggest for the first time that the dependence on NRF2 observed in mutated KRAS malignant cells makes them more sensitive to the cytotoxic effect of DMF, which thus opens up new prospects for the therapeutic applications of DMF. Dimethyl Fumarate 236-239 NFE2 like bZIP transcription factor 2 Homo sapiens 62-66 28156185-0 2017 Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies. Dimethyl Fumarate 103-120 NFE2 like bZIP transcription factor 2 Homo sapiens 30-34 28156185-2 2017 Preclinical studies demonstrated that DMF activated the nuclear factor E2-related factor 2 (Nrf2) pathway. Dimethyl Fumarate 38-41 NFE2 like bZIP transcription factor 2 Homo sapiens 92-96 28156185-3 2017 DMF and its primary metabolite monomethyl fumarate (MMF) were also shown to promote cytoprotection of cultured central nervous system (CNS) cells via the Nrf2 pathway. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 154-158 28156185-4 2017 OBJECTIVE: To investigate the activation of Nrf2 pathway following ex vivo stimulation of human peripheral blood mononuclear cells (PBMCs) with DMF or MMF, and in DMF-treated patients from two Phase 3 relapsing MS studies DEFINE and CONFIRM. Dimethyl Fumarate 163-166 NFE2 like bZIP transcription factor 2 Homo sapiens 44-48 28156185-11 2017 CONCLUSION: These data provide the first evidence of Nrf2 pathway activation from two large pivotal Phase 3 studies of DMF-treated MS patients. Dimethyl Fumarate 119-122 NFE2 like bZIP transcription factor 2 Homo sapiens 53-57 29096692-2 2017 In central nervous system (CNS) cells, DMF activates nuclear factor E2-related factor 2 (Nrf2), perhaps ameliorating oxidative stress-induced damage. Dimethyl Fumarate 39-42 NFE2 like bZIP transcription factor 2 Homo sapiens 89-93 29209333-2 2017 Dimethyl fumarate (DMF), an activator of Nrf2, has been shown to have anti-inflammatory and immunomodulatory properties without significant immunosuppression. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 41-45 29209333-2 2017 Dimethyl fumarate (DMF), an activator of Nrf2, has been shown to have anti-inflammatory and immunomodulatory properties without significant immunosuppression. Dimethyl Fumarate 19-22 NFE2 like bZIP transcription factor 2 Homo sapiens 41-45 29096692-3 2017 However, it is not known whether DMF also activates Nrf2 in peripheral immune cells, which are known to participate in CNS demyelination. Dimethyl Fumarate 33-36 NFE2 like bZIP transcription factor 2 Homo sapiens 52-56 29096692-4 2017 We conducted a single observation study to determine whether DMF can activate Nrf2 in peripheral immune cells in vitro. Dimethyl Fumarate 61-64 NFE2 like bZIP transcription factor 2 Homo sapiens 78-82 29096692-5 2017 RESULTS: We performed enzyme-linked immunosorbent assays to measure Nrf2 activation in nuclear extracts of human peripheral blood mononuclear cells treated with DMF at time points from 0 to 6 h, initially determining that DMF did not activate Nrf2, and that the mechanism(s) of action of DMF may thus differ in the periphery compared to the CNS. Dimethyl Fumarate 161-164 NFE2 like bZIP transcription factor 2 Homo sapiens 68-72 29096692-5 2017 RESULTS: We performed enzyme-linked immunosorbent assays to measure Nrf2 activation in nuclear extracts of human peripheral blood mononuclear cells treated with DMF at time points from 0 to 6 h, initially determining that DMF did not activate Nrf2, and that the mechanism(s) of action of DMF may thus differ in the periphery compared to the CNS. Dimethyl Fumarate 222-225 NFE2 like bZIP transcription factor 2 Homo sapiens 243-247 29096692-5 2017 RESULTS: We performed enzyme-linked immunosorbent assays to measure Nrf2 activation in nuclear extracts of human peripheral blood mononuclear cells treated with DMF at time points from 0 to 6 h, initially determining that DMF did not activate Nrf2, and that the mechanism(s) of action of DMF may thus differ in the periphery compared to the CNS. Dimethyl Fumarate 222-225 NFE2 like bZIP transcription factor 2 Homo sapiens 243-247 29046485-5 2017 DMF recruited Nrf2 to the gamma-globin promoters and the locus control region of the beta-globin locus in erythroleukemia cells, elevated HbF in SCD donor-derived erythroid progenitors, and reduced hypoxia-induced sickling. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 14-18 28918452-7 2017 DMF may exert an additive therapeutic efficacy in PV by attenuating the redox burden and subsequent oxidative damage to normal keratinocytes through activation of Nrf2 pathway relative to PV. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 163-167 28006954-5 2017 Furthermore, DMF treatment upregulated the Nrf-2 pathway, increased NeuN+/Nrf-2+ cell number in the striatum, induced activation of manganese superoxide dismutase and heme oxygenase-1, and regulated glutathione levels. Dimethyl Fumarate 13-16 NFE2 like bZIP transcription factor 2 Homo sapiens 43-48 28006954-5 2017 Furthermore, DMF treatment upregulated the Nrf-2 pathway, increased NeuN+/Nrf-2+ cell number in the striatum, induced activation of manganese superoxide dismutase and heme oxygenase-1, and regulated glutathione levels. Dimethyl Fumarate 13-16 NFE2 like bZIP transcription factor 2 Homo sapiens 74-79 28006954-8 2017 The protective effects of DMF treatment, via Nrf-2, were confirmed in in vitro studies, through inhibition of Nrf-2 by trigonelline. Dimethyl Fumarate 26-29 NFE2 like bZIP transcription factor 2 Homo sapiens 45-50 28006954-8 2017 The protective effects of DMF treatment, via Nrf-2, were confirmed in in vitro studies, through inhibition of Nrf-2 by trigonelline. Dimethyl Fumarate 26-29 NFE2 like bZIP transcription factor 2 Homo sapiens 110-115 28460056-3 2017 The induction of mitochondrial gene expression is more dependent on DMF"s target Nrf2 than hydroxycarboxylic acid receptor 2 (HCAR2). Dimethyl Fumarate 68-71 NFE2 like bZIP transcription factor 2 Homo sapiens 81-85 28460056-4 2017 Thus, DMF induces mitochondrial biogenesis primarily through its action on Nrf2, and is the first drug demonstrated to increase mitochondrial biogenesis with in vivo human dosing. Dimethyl Fumarate 6-9 NFE2 like bZIP transcription factor 2 Homo sapiens 75-79 28108787-0 2017 Dimethyl fumarate accelerates peripheral nerve regeneration via activation of the anti-inflammatory and cytoprotective Nrf2/HO-1 signaling pathway. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 119-123 28429615-8 2017 Activation of Nrf2 by dimethyl fumarate preserved BK-beta1 expression and protected BK channel and vascular function in db/db coronary arteries. Dimethyl Fumarate 22-39 NFE2 like bZIP transcription factor 2 Homo sapiens 14-18 28370349-8 2017 Dimethyl fumarate-mediated NRF2 activation protected normal and vitiligo melanocytes against monobenzone-induced toxicity. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 27-31 28247911-6 2017 In contrast, Nrf2-activating compounds, including the anti-inflammatory drug dimethyl fumarate (DMF), inhibit inflammasome activation. Dimethyl Fumarate 77-94 NFE2 like bZIP transcription factor 2 Homo sapiens 13-17 28247911-6 2017 In contrast, Nrf2-activating compounds, including the anti-inflammatory drug dimethyl fumarate (DMF), inhibit inflammasome activation. Dimethyl Fumarate 96-99 NFE2 like bZIP transcription factor 2 Homo sapiens 13-17 28069874-0 2017 Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 31-35 28069874-3 2017 Dimethyl fumarate (DMF) is known to promote NRF2 activity in noncancer models. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 44-48 28069874-3 2017 Dimethyl fumarate (DMF) is known to promote NRF2 activity in noncancer models. Dimethyl Fumarate 19-22 NFE2 like bZIP transcription factor 2 Homo sapiens 44-48 28069874-5 2017 We demonstrated that at lower concentrations (<25 mumol/L), DMF has a cytoprotective role through activation of the NRF2 antioxidant pathway. Dimethyl Fumarate 63-66 NFE2 like bZIP transcription factor 2 Homo sapiens 119-123 28069874-7 2017 High DMF concentration decreases nuclear translocation of NRF2 and production of its downstream targets. Dimethyl Fumarate 5-8 NFE2 like bZIP transcription factor 2 Homo sapiens 58-62 28069874-8 2017 The pro-oxidative and cytotoxic effects of high concentration of DMF were abrogated by overexpression of NRF2 in OVCAR3 cells, suggesting that DMF cytotoxicity is dependent of NRF2 depletion. Dimethyl Fumarate 65-68 NFE2 like bZIP transcription factor 2 Homo sapiens 105-109 28069874-8 2017 The pro-oxidative and cytotoxic effects of high concentration of DMF were abrogated by overexpression of NRF2 in OVCAR3 cells, suggesting that DMF cytotoxicity is dependent of NRF2 depletion. Dimethyl Fumarate 65-68 NFE2 like bZIP transcription factor 2 Homo sapiens 176-180 28069874-8 2017 The pro-oxidative and cytotoxic effects of high concentration of DMF were abrogated by overexpression of NRF2 in OVCAR3 cells, suggesting that DMF cytotoxicity is dependent of NRF2 depletion. Dimethyl Fumarate 143-146 NFE2 like bZIP transcription factor 2 Homo sapiens 105-109 28069874-8 2017 The pro-oxidative and cytotoxic effects of high concentration of DMF were abrogated by overexpression of NRF2 in OVCAR3 cells, suggesting that DMF cytotoxicity is dependent of NRF2 depletion. Dimethyl Fumarate 143-146 NFE2 like bZIP transcription factor 2 Homo sapiens 176-180 28069874-9 2017 High concentrations of DMF decreased the expression of DJ-1, a NRF2 protein stabilizer. Dimethyl Fumarate 23-26 NFE2 like bZIP transcription factor 2 Homo sapiens 63-67 28069874-12 2017 Taken together, these findings implicate the effect of DJ-1 on NRF2 in cancer development and identify DMF as a dose-dependent modulator of both NRF2 and DJ-1, which may be useful in exploiting the therapeutic potential of these endogenous antioxidants. Dimethyl Fumarate 103-106 NFE2 like bZIP transcription factor 2 Homo sapiens 145-149 28181536-1 2017 Dimethyl fumarate (DMF) is indicated for the treatment of relapsing multiple sclerosis and may exert therapeutic effects via activation of the nuclear factor (erythroid-derived 2)-like 2 (NRF2) pathway. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 188-192 28181536-1 2017 Dimethyl fumarate (DMF) is indicated for the treatment of relapsing multiple sclerosis and may exert therapeutic effects via activation of the nuclear factor (erythroid-derived 2)-like 2 (NRF2) pathway. Dimethyl Fumarate 19-22 NFE2 like bZIP transcription factor 2 Homo sapiens 188-192 28181536-2 2017 Following oral DMF administration, central nervous system (CNS) tissue is predominantly exposed to monomethyl fumarate (MMF), the bioactive metabolite of DMF, which can stabilize NRF2 and induce antioxidant gene expression; however, the detailed NRF2-dependent mechanisms modulated by MMF that lead to cytoprotection are unknown. Dimethyl Fumarate 15-18 NFE2 like bZIP transcription factor 2 Homo sapiens 179-183 28181536-2 2017 Following oral DMF administration, central nervous system (CNS) tissue is predominantly exposed to monomethyl fumarate (MMF), the bioactive metabolite of DMF, which can stabilize NRF2 and induce antioxidant gene expression; however, the detailed NRF2-dependent mechanisms modulated by MMF that lead to cytoprotection are unknown. Dimethyl Fumarate 15-18 NFE2 like bZIP transcription factor 2 Homo sapiens 246-250 28181536-2 2017 Following oral DMF administration, central nervous system (CNS) tissue is predominantly exposed to monomethyl fumarate (MMF), the bioactive metabolite of DMF, which can stabilize NRF2 and induce antioxidant gene expression; however, the detailed NRF2-dependent mechanisms modulated by MMF that lead to cytoprotection are unknown. Dimethyl Fumarate 154-157 NFE2 like bZIP transcription factor 2 Homo sapiens 179-183 28181536-2 2017 Following oral DMF administration, central nervous system (CNS) tissue is predominantly exposed to monomethyl fumarate (MMF), the bioactive metabolite of DMF, which can stabilize NRF2 and induce antioxidant gene expression; however, the detailed NRF2-dependent mechanisms modulated by MMF that lead to cytoprotection are unknown. Dimethyl Fumarate 154-157 NFE2 like bZIP transcription factor 2 Homo sapiens 246-250 27192495-3 2016 The Nrf2 activator DMF (Dimethylfumarates) has been approved by the FDA as a new first-line oral drug to treat patients with relapsing forms of multiple sclerosis, while a phase 3 study of another promising candidate, CDDO-Me, was terminated for safety reasons. Dimethyl Fumarate 19-22 NFE2 like bZIP transcription factor 2 Homo sapiens 4-8 29363907-9 2017 This indicates that the regulation of the Nrf2-dependent antioxidant pathway by DMF occurs at a certain time interval (early EAE/MS) and strongly underlines the importance of the earliest introduction of the therapy to the patient. Dimethyl Fumarate 80-83 NFE2 like bZIP transcription factor 2 Homo sapiens 42-46 28116039-3 2017 DMF activates the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) leading to increased synthesis of the major cellular antioxidant glutathione (GSH) and prominent neuroprotection in vitro. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 39-82 28116039-3 2017 DMF activates the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) leading to increased synthesis of the major cellular antioxidant glutathione (GSH) and prominent neuroprotection in vitro. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 84-88 27725119-4 2016 Additionally, through an NRF2 independent manner, DMF, but not MMF significantly reduced production of proinflammatory mediators in classically activated microglia, and further rescued mitochondrial respiratory deficits in primary cortical neurons that were induced by activated microglia. Dimethyl Fumarate 50-53 NFE2 like bZIP transcription factor 2 Homo sapiens 25-29 27192495-3 2016 The Nrf2 activator DMF (Dimethylfumarates) has been approved by the FDA as a new first-line oral drug to treat patients with relapsing forms of multiple sclerosis, while a phase 3 study of another promising candidate, CDDO-Me, was terminated for safety reasons. Dimethyl Fumarate 24-41 NFE2 like bZIP transcription factor 2 Homo sapiens 4-8 27009601-0 2016 Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson"s Disease. Dimethyl Fumarate 31-48 NFE2 like bZIP transcription factor 2 Homo sapiens 16-20 27009601-2 2016 RESULTS: Pharmacological activation of NRF2 was achieved at the basal ganglia by repurposing dimethyl fumarate (DMF), a drug already in use for the treatment of multiple sclerosis. Dimethyl Fumarate 93-110 NFE2 like bZIP transcription factor 2 Homo sapiens 39-43 27009601-2 2016 RESULTS: Pharmacological activation of NRF2 was achieved at the basal ganglia by repurposing dimethyl fumarate (DMF), a drug already in use for the treatment of multiple sclerosis. Dimethyl Fumarate 112-115 NFE2 like bZIP transcription factor 2 Homo sapiens 39-43 27009601-7 2016 INNOVATION: These experiments provide a compelling rationale for targeting NRF2 with DMF as a therapeutic strategy to reinforce endogenous brain defense mechanisms against PD-associated synucleinopathy. Dimethyl Fumarate 85-88 NFE2 like bZIP transcription factor 2 Homo sapiens 75-79 26044512-6 2015 We provide here a brief review of a few clinically-used drugs that can up-regulate Nrf2 with the potential of extending their usage to diabetic patients for the prevention of cardiovascular complications and conclude with a closer inspection of dimethyl fumarate and its mimic members. Dimethyl Fumarate 245-262 NFE2 like bZIP transcription factor 2 Homo sapiens 83-87 27774309-1 2016 This systematic and comprehensive study reports for the first time on the successful rational design of advanced inhalable therapeutic dry powders containing dimethyl fumarate, a first-in-class Nrf2 activator drug to treat pulmonary inflammation, using particle engineering design technology for targeted delivery to the lungs as advanced spray dried (SD) one-component DPIs. Dimethyl Fumarate 158-175 NFE2 like bZIP transcription factor 2 Homo sapiens 194-198 27725581-5 2016 An NRF2 inducer, BG-12, was recently approved as a drug for multiple sclerosis. Dimethyl Fumarate 17-22 NFE2 like bZIP transcription factor 2 Homo sapiens 3-7 26188148-3 2015 Here we investigated the effect of the Nrf2 activators dimethylfumarate (DMF) and carnosol on antioxidant pathways, oxygen consumption rate and wound healing in human retinal pigment epithelial cells (ARPE-19) cultured in medium containing normal (NG, 5mM) or high (HG, 25 mM) glucose levels. Dimethyl Fumarate 55-71 NFE2 like bZIP transcription factor 2 Homo sapiens 39-43 26188148-3 2015 Here we investigated the effect of the Nrf2 activators dimethylfumarate (DMF) and carnosol on antioxidant pathways, oxygen consumption rate and wound healing in human retinal pigment epithelial cells (ARPE-19) cultured in medium containing normal (NG, 5mM) or high (HG, 25 mM) glucose levels. Dimethyl Fumarate 73-76 NFE2 like bZIP transcription factor 2 Homo sapiens 39-43 26188148-5 2015 We found that Nrf2 nuclear translocation and heme oxygenase activity increased in ARPE cells treated with 10 muM DMF or carnosol irrespective of glucose culture conditions. Dimethyl Fumarate 113-116 NFE2 like bZIP transcription factor 2 Homo sapiens 14-18 26004161-0 2015 DMF, but not other fumarates, inhibits NF-kappaB activity in vitro in an Nrf2-independent manner. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 73-77 26004161-4 2015 We demonstrate that DMF inhibited NF-kappaB-driven cytokine production and nuclear translocation of p65 and p52 in an Nrf2-independent manner. Dimethyl Fumarate 20-23 NFE2 like bZIP transcription factor 2 Homo sapiens 118-122 25019514-5 2014 Traditional small molecules targeting ARE-regulated gene activation (e.g., bardoxolone, dimethyl fumarate) function by alkylating numerous proteins including Keap1, the controlling protein of Nrf2. Dimethyl Fumarate 88-105 NFE2 like bZIP transcription factor 2 Homo sapiens 192-196 25793262-7 2015 Consistent with KEAP1 cysteine modification, DMF treatment resulted in nuclear translocation of NRF2 and a robust transcriptional response in treated cells, as did MEF; however, the responses to MEF were of a lower magnitude or distinct compared to DMF. Dimethyl Fumarate 45-48 NFE2 like bZIP transcription factor 2 Homo sapiens 96-100 25584071-4 2015 More importantly, DMF was discovered to impact the anti-oxidative stress cell machinery promoting the transcription of genes downstream to the activation of the nuclear factor (erythroid derived 2)-like2 (NRF2). Dimethyl Fumarate 18-21 NFE2 like bZIP transcription factor 2 Homo sapiens 205-209 25584071-5 2015 DMF exposure increases the cytosol concentrations of NRF2, which besides immune regulatory effects, has the potential for cytoprotection on glial cells, oligodendrocytes and neurons. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 53-57 25303683-1 2015 We hypothesized that O2 tension influences the redox state and the immunomodulatory responses of inflammatory cells to dimethyl fumarate (DMF), an activator of the nuclear factor Nrf2 that controls antioxidant genes expression. Dimethyl Fumarate 119-136 NFE2 like bZIP transcription factor 2 Homo sapiens 179-183 25303683-1 2015 We hypothesized that O2 tension influences the redox state and the immunomodulatory responses of inflammatory cells to dimethyl fumarate (DMF), an activator of the nuclear factor Nrf2 that controls antioxidant genes expression. Dimethyl Fumarate 138-141 NFE2 like bZIP transcription factor 2 Homo sapiens 179-183 25793262-0 2015 Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 80-84 25793262-3 2015 Previous studies have provided insight into the pharmacologic properties of DMF, including modulation of kelch-like ECH-associated protein 1 (KEAP1), activation of the nuclear factor (erythroid-derived 2)-like 2 (NRF2) pathway, and glutathione (GSH) modulation; however, those of MEF remain largely unexplored. Dimethyl Fumarate 76-79 NFE2 like bZIP transcription factor 2 Homo sapiens 213-217 25449120-0 2015 Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson"s disease by enhancing Nrf2 activity. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 131-135 25449120-3 2015 Treatment of animals and dopaminergic SH-SY5Y cells with DMF resulted in increased nuclear levels of active Nrf2, with subsequent upregulation of antioxidant target genes. Dimethyl Fumarate 57-60 NFE2 like bZIP transcription factor 2 Homo sapiens 108-112 25449120-6 2015 The neuroprotective effects of DMF against 6-OHDA neurotoxicity were dependent on Nrf2, since treatment with Nrf2 siRNA failed to block against 6-OHDA neurotoxicity and induce Nrf2-dependent cytoprotective genes in SH-SY5Y cells. Dimethyl Fumarate 31-34 NFE2 like bZIP transcription factor 2 Homo sapiens 82-86 25449120-6 2015 The neuroprotective effects of DMF against 6-OHDA neurotoxicity were dependent on Nrf2, since treatment with Nrf2 siRNA failed to block against 6-OHDA neurotoxicity and induce Nrf2-dependent cytoprotective genes in SH-SY5Y cells. Dimethyl Fumarate 31-34 NFE2 like bZIP transcription factor 2 Homo sapiens 109-113 25449120-6 2015 The neuroprotective effects of DMF against 6-OHDA neurotoxicity were dependent on Nrf2, since treatment with Nrf2 siRNA failed to block against 6-OHDA neurotoxicity and induce Nrf2-dependent cytoprotective genes in SH-SY5Y cells. Dimethyl Fumarate 31-34 NFE2 like bZIP transcription factor 2 Homo sapiens 109-113 25842911-2 2015 Dimethyl fumarate shows anti-inflammatory and cytoprotective properties that are thought to be mediated primarily via activation of the nuclear factor (erythroid-derived 2)-like 2- Nrf2 transcriptional pathway, which up-regulates the genes involved in the cellular response to oxidative stress. Dimethyl Fumarate 0-17 NFE2 like bZIP transcription factor 2 Homo sapiens 181-185 24131282-5 2014 FINDINGS: Data from preclinical studies have demonstrated that BG-12 may promote anti-inflammatory and cytoprotective activities that are mediated, at least in part, by the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) antioxidant response pathway. Dimethyl Fumarate 63-68 NFE2 like bZIP transcription factor 2 Homo sapiens 173-216 25009787-0 2014 Dimethylfumarate attenuates restenosis after acute vascular injury by cell-specific and Nrf2-dependent mechanisms. Dimethyl Fumarate 0-16 NFE2 like bZIP transcription factor 2 Homo sapiens 88-92 25009787-2 2014 We tested if dimethylfumarate (DMF), an anti-psoriasis drug, could inhibit abnormal vascular remodeling via NF-E2-related factor 2 (Nrf2)-NAD(P)H quinone oxidoreductase 1 (NQO1) activity. Dimethyl Fumarate 13-29 NFE2 like bZIP transcription factor 2 Homo sapiens 132-136 25009787-2 2014 We tested if dimethylfumarate (DMF), an anti-psoriasis drug, could inhibit abnormal vascular remodeling via NF-E2-related factor 2 (Nrf2)-NAD(P)H quinone oxidoreductase 1 (NQO1) activity. Dimethyl Fumarate 31-34 NFE2 like bZIP transcription factor 2 Homo sapiens 132-136 25009787-4 2014 Initially, DMF increased p21 protein stability through an enhancement in Nrf2 activity without an increase in p21 mRNA. Dimethyl Fumarate 11-14 NFE2 like bZIP transcription factor 2 Homo sapiens 73-77 25009787-8 2014 With knock-down of Nrf2 or NQO1, DMF failed to prevent TNF-alpha-induced cell apoptosis and decreased eNOS expression. Dimethyl Fumarate 33-36 NFE2 like bZIP transcription factor 2 Homo sapiens 19-23 25009787-10 2014 In conclusion, DMF prevented abnormal proliferation in VSMCs by G1 cell cycle arrest via p21 upregulation driven by Nrf2 and p53 activity, and had a beneficial effect on TNF-alpha-induced apoptosis and dysfunction in endothelial cells through Nrf2-NQO1 activity suggesting that DMF might be a therapeutic drug for patients with vascular disease. Dimethyl Fumarate 15-18 NFE2 like bZIP transcription factor 2 Homo sapiens 116-120 25009787-10 2014 In conclusion, DMF prevented abnormal proliferation in VSMCs by G1 cell cycle arrest via p21 upregulation driven by Nrf2 and p53 activity, and had a beneficial effect on TNF-alpha-induced apoptosis and dysfunction in endothelial cells through Nrf2-NQO1 activity suggesting that DMF might be a therapeutic drug for patients with vascular disease. Dimethyl Fumarate 15-18 NFE2 like bZIP transcription factor 2 Homo sapiens 243-247 24131282-5 2014 FINDINGS: Data from preclinical studies have demonstrated that BG-12 may promote anti-inflammatory and cytoprotective activities that are mediated, at least in part, by the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) antioxidant response pathway. Dimethyl Fumarate 63-68 NFE2 like bZIP transcription factor 2 Homo sapiens 218-222 23709213-3 2013 DMF acts through chemical modification of the repressor protein Keap1, allowing stabilization and nuclear translocation of the transcription factor Nrf2, with subsequent downstream activation of a cascade of several cytoprotective and antioxidant pathways. Dimethyl Fumarate 0-3 NFE2 like bZIP transcription factor 2 Homo sapiens 148-152 24076006-6 2013 We show that dimethylfumarate (DMF) and its primary metabolite monomethylfumarate (MMF) induce the expression of the Nrf2/NQO1 pathway in endothelial cells. Dimethyl Fumarate 13-29 NFE2 like bZIP transcription factor 2 Homo sapiens 117-121 24076006-6 2013 We show that dimethylfumarate (DMF) and its primary metabolite monomethylfumarate (MMF) induce the expression of the Nrf2/NQO1 pathway in endothelial cells. Dimethyl Fumarate 31-34 NFE2 like bZIP transcription factor 2 Homo sapiens 117-121 23637829-3 2013 Dimethylfumarate (DMF), an immune modulator and antioxidant, may function as an inhibitor of STAT3 and an activator of Nrf2. Dimethyl Fumarate 0-16 NFE2 like bZIP transcription factor 2 Homo sapiens 119-123 23637829-3 2013 Dimethylfumarate (DMF), an immune modulator and antioxidant, may function as an inhibitor of STAT3 and an activator of Nrf2. Dimethyl Fumarate 18-21 NFE2 like bZIP transcription factor 2 Homo sapiens 119-123 23637829-4 2013 This study examined whether DMF inhibits adipogenic differentiation of 3T3-L1 preadipocytes by inhibiting STAT3 or activating Nrf2. Dimethyl Fumarate 28-31 NFE2 like bZIP transcription factor 2 Homo sapiens 126-130 22769044-7 2012 Our observations show that dimethyl fumarate causes short-lived oxidative stress, which leads to increased levels and nuclear localization of the transcription factor nuclear factor erythroid 2-related factor 2 and a subsequent increase in glutathione synthesis and recycling in neuronal cells. Dimethyl Fumarate 27-44 NFE2 like bZIP transcription factor 2 Homo sapiens 167-210 23109883-6 2012 In vitro, application of dimethylfumarate (DMF) leads to stabilization of Nrf2, activation of Nrf2-dependent transcriptional activity and abundant synthesis of detoxifying proteins. Dimethyl Fumarate 25-41 NFE2 like bZIP transcription factor 2 Homo sapiens 74-78 23109883-6 2012 In vitro, application of dimethylfumarate (DMF) leads to stabilization of Nrf2, activation of Nrf2-dependent transcriptional activity and abundant synthesis of detoxifying proteins. Dimethyl Fumarate 25-41 NFE2 like bZIP transcription factor 2 Homo sapiens 94-98 23109883-6 2012 In vitro, application of dimethylfumarate (DMF) leads to stabilization of Nrf2, activation of Nrf2-dependent transcriptional activity and abundant synthesis of detoxifying proteins. Dimethyl Fumarate 43-46 NFE2 like bZIP transcription factor 2 Homo sapiens 74-78 23109883-6 2012 In vitro, application of dimethylfumarate (DMF) leads to stabilization of Nrf2, activation of Nrf2-dependent transcriptional activity and abundant synthesis of detoxifying proteins. Dimethyl Fumarate 43-46 NFE2 like bZIP transcription factor 2 Homo sapiens 94-98